Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats

Pharmacological Research

Volumn 55, Issue 1, 2007, Pages 64-71

  Li, Fuhai ^a   Xia, Wei ^a   Li, Aiwu ^a   Zhao, Cuifen ^a   Sun, Ruopeng ^a  

^a Qilu Hospital of Shandong University   (China)

Author keywords

Congenital; Fasudil; Heart defects; Hypertension; Pulmonary; Rho associated kinase; Smooth muscle cell

Indexed keywords

CYCLINE; FASUDIL; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTERY MEDIA; ARTERY MUSCLE; ARTERY WALL; ARTICLE; BLOOD FLOW VELOCITY; CELL PROLIFERATION; COMMON CAROTID ARTERY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; EXTERNAL JUGULAR VEIN; HEART LEFT VENTRICLE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HEART VENTRICLE SEPTUM; HEART WEIGHT; HEMODYNAMIC MONITORING; LUNG HEMODYNAMICS; MALE; MORPHOLOGY; NICK END LABELING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SHUNTING; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; THICKNESS; TREATMENT OUTCOME; WISTAR RAT;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; APOPTOSIS; BLOOD GAS ANALYSIS; BLOOD PRESSURE; BLOTTING, WESTERN; CELL PROLIFERATION; ENZYME INHIBITORS; IN SITU NICK-END LABELING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG; MALE; PROTEIN-SERINE-THREONINE KINASES; PULMONARY ARTERY; RATS; RATS, WISTAR; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; STROKE VOLUME;

EID: 33846194678     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.10.009     Document Type: Article

References (33)

1. Dzau V.J., and Gibbons G.H. Vascular remodeling: mechanisms and implications. J Cardiovasc Pharmacol 21 Suppl. 1 (1993) S1-S5
2. Gibbons G.H., and Dzau V.J. The emerging concept of vascular remodeling. N Engl J Med 330 (1994) 1431-1438
3. Rubin L.J. Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol 75 (1995) 51A-54A
4. Runo J.R., and Loyd J.E. Primary pulmonary hypertension. Lancet 361 (2003) 1533-1544
5. Hall A. Rho GTPases and the actin cytoskeleton. Science 279 (1998) 509-514
6. Narumiya S. The small GTPase Rho: cellular functions and signal transduction. J Biochem (Tokyo) 120 (1996) 215-228
7. Chihara K., Amano M., Nakamura N., Yano T., Shibata M., Tokui T., et al. Cytoskeletal rearrangements and transcriptional activation of c-fos serum response element by Rho-kinase. J Biol Chem 272 (1997) 25121-25127
8. Numaguchi K., Eguchi S., Yamakawa T., Motley E.D., and Inagami T. Mechanotransduction of rat aortic vascular smooth muscle cells requires RhoA and intact actin filaments. Circ Res 85 (1999) 5-11
9. Katsumi A., Milanini J., Kiosses W.B., del Pozo M.A., Kaunas R., Chien S., et al. Effects of cell tension on the small GTPase Rac. J Cell Biol 158 (2002) 153-164
10. Fagan K.A., Oka M., Bauer N.R., Gebb S.A., Ivy D.D., Morris K.G., et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 287 (2004) L656-L664
11. Nagaoka T., Morio Y., Casanova N., Bauer N., Gebb S., McMurtry I., et al. Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 287 (2004) L665-L672
12. Abe K., Shimokawa H., Morikawa K., Uwatoku T., Oi K., Matsumoto Y., et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 94 (2004) 385-393
13. Guilluy C., Sauzeau V., Rolli-Derkinderen M., Guerin P., Sagan C., Pacaud P., et al. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 146 (2005) 1010-1018
14. Okubo S., Nakai M., and Tomino T. Relevance of location of defect and pulmonary vascular resistance to the intracardiac pattern of left-to-right shunt flow in dogs with experimental ventricular septal defect. Circulation 73 (1986) 775-783
15. Liu Z.M., Guan Z.J., and Shen W.L. Application of sleeve anastomosis in development of cervical heart transplantation in rats. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 18 (2004) 63-65
16. Choe K.O., Cho B.K., Choi B.W., Park C.I., and Lee S.K. Histologic changes of pulmonary arteries in congenital heart disease with left-to-right shunt (part 1): correlated with preoperative pulmonary hemodynamics. Emphasizing the significance of pulmonary arterial concentration. Yonsei Med J 43 (2002) 73-81
17. Li X.H., Du J.B., Tang X.Y., Jin H.F., and Tang C.S. Changes of pulmonary artery structural remodeling in pulmonary hypertension induced by high pulmonary flow in rats. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 27 (2005) 446-451
18. Putnam A.J., Cunningham J.J., Pillemer B.B., and Mooney D.J. External mechanical strain regulates membrane targeting of Rho GTPases by controlling microtubule assembly. Am J Physiol Cell Physiol 284 (2003) C627-C639
19. Williams B. Mechanical influences on vascular smooth muscle cell function. J Hypertens 16 (1998) 1921-1929
20. Wilson E., Mai Q., Sudhir K., Weiss R.H., and Ives H.E. Mechanical strain induces growth of vascular smooth muscle cells via autocrine action of PDGF. J Cell Biol 123 (1993) 741-747
21. Wilson E., Sudhir K., and Ives H.E. Mechanical strain of rat vascular smooth muscle cells is sensed by specific extracellular matrix/integrin interactions. J Clin Invest 96 (1995) 2364-2372
22. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 39 (2002) 319-327
23. Matsumoto Y., Uwatoku T., Oi K., Abe K., Hattori T., Morishige K., et al. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol 24 (2004) 181-186
24. Hattori T., Shimokawa H., Higashi M., Hiroki J., Mukai Y., Kaibuchi K., et al. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res 94 (2004) 46-52
25. Funakoshi Y., Ichiki T., Shimokawa H., Egashira K., Takeda K., Kaibuchi K., et al. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 38 (2001) 100-104
26. Hiroki J., Shimokawa H., Higashi M., Morikawa K., Kandabashi T., Kawamura N., et al. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol 37 (2004) 537-546
27. Higashi M., Shimokawa H., Hattori T., Hiroki J., Mukai Y., Morikawa K., et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 93 (2003) 767-775
28. Liu Y., Suzuki Y.J., Day R.M., and Fanburg B.L. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res 95 (2004) 579-586
29. Seasholtz T.M., Majumdar M., Kaplan D.D., and Brown J.H. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 84 (1999) 1186-1193
30. Shimokawa H., Seto M., Katsumata N., Amano M., Kozai T., Yamawaki T., et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res 43 (1999) 1029-1039
31. Sauzeau V., Le Mellionnec E., Bertoglio J., Scalbert E., Pacaud P., and Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88 (2001) 1102-1104
32. Mukai Y., Shimokawa H., Matoba T., Kandabashi T., Satoh S., Hiroki J., et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J 15 (2001) 1062-1064
33. Masumoto A., Mohri M., Shimokawa H., Urakami L., Usui M., and Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105 (2002) 1545-1547